Please login to the form below
bladder cancer
This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.
Merck receives FDA approval for Keytruda combination in gastric cancer
An estimated 26, 500 people in the US will be diagnosed with gastric cancer in 2023. ... Beyond gastric cancer, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s lymphoma.
Latest news
-
Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial
of disease across multiple types of cancer, we hope to reduce disease recurrence and ultimately improve overall survival outcomes. ... Beyond RCC, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer,
-
Merck’s Keytruda combination granted FDA approval for biliary tract cancer
Beyond BTC, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s lymphoma. ... Last month, the therapy was approved in the US as part of a combination treatment for patients
-
Merck’s Keytruda granted FDA approval for expanded use in lung cancer
The approval marks the sixth non-small cell lung cancer indication for the anti-PD-1 therapy. ... Beyond lung cancer, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s
-
Merck shares positive results for Keytruda in phase 3 bladder cancer study
Over 82, 000 people in the US will be be diagnosed with bladder cancer in 2023. ... The therapy already holds approvals to treat a wide variety of cancers, including specific cases of locally advanced or metastatic urothelial carcinoma and
-
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition
At the time of the announcement, Pfizer's oncology portfolio included 24 approved drugs, while Seagen's included Adcetris for lymphomas, Padcev for bladder cancers, Tivdak for cervical cancer, and Tukysa ... the deal could reduce competition in the
More from news
Approximately 34 fully matching, plus 135 partially matching documents found.
Latest Intelligence
-
Improving outcomes for prostate cancer patients
a later stage, where it is more likely that the cancer is less treatable. ... Unlike the female equivalent – breast cancer – there is no automatic screening for prostate cancer.
-
Unlocking the potential of precision medicine in oncology
those living with urothelial carcinoma (UC), the most common type of bladder cancer. ... and metastatic bladder cancer harbouring an FGFR alteration, addressing the considerable unmet need for patients living with this disease.
-
Surviving cancer: a new era for patients
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.
-
Cancer immunotherapy: What's on the horizon?
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
-
Deal Watch October 2015
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New hires at Ferring, Flexion and Immunocore
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A reflection of ESMO
The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
